Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation

被引：5
|
作者：
Morgensztern, Daniel [1 ]
Govindan, Ramaswamy [1 ]
机构：
[1] Washington Univ, Div Med Oncol, Dept Med, Sch Med, St Louis, MO 63110 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 12期
关键词：
CELL LUNG-CANCER; CHECKPOINT INHIBITORS; SURVIVAL;
D O I：
10.1016/j.jtho.2021.07.034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1999 / 2001
页数：3
相关论文
共 50 条
  • [1] Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC
    V. Aredo, Jacqueline
    Hellyer, Jessica A.
    Neal, Joel W.
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 1994 - 1998
  • [2] Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC "
    Chen, Ching-Yi
    Wang, Guo-Sheng
    Wei, James Cheng-Chung
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05) : e6 - e7
  • [3] Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
    Zhao, Binghao
    Yao, Longping
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05)
  • [4] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
  • [5] Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
    Nassar, Amin H.
    Kim, So Yeon
    Aredo, Jacqueline, V
    Feng, Jamie
    Shepherd, Frances
    Xu, Chao
    Kaldas, David
    Gray, Jhanelle E.
    Dilling, Thomas J.
    Neal, Joel W.
    Wakelee, Heather A.
    Liu, Yufei
    Lin, Steven H.
    Abuali, Tariq
    Amini, Arya
    Nie, Yunan
    Patil, Tejas
    Lobachov, Anastasiya
    Bar, Jair
    Fitzgerald, Bailey
    Fujiwara, Yu
    Marron, Thomas U.
    Thummalapalli, Rohit
    Yu, Helena
    Owen, Dwight H.
    Sharp, John
    Farid, Saira
    Rocha, Pedro
    Arriola, Edurne
    'Aiello, Angelica
    Cheng, Haiying
    Whitaker, Ryan
    Parikh, Kaushal
    Ashara, Yash
    Chen, Luxi
    Sankar, Kamya
    Harris, Jeremy P.
    Nagasaka, Misako
    Ayanambakkam, Adanma
    Velazquez, Ana I.
    Ragavan, Meera
    Lin, Jessica J.
    Piotrowska, Zo fia
    Wilgucki, Molly
    Reuss, Joshua
    Luders, Heike
    Grohe, Christian
    Espinar, Javier Baena
    Feiner, Ella
    Punekar, Salman R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (06) : 928 - 940
  • [6] The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
    Chang, Allison E. B.
    Piper-Vallillo, Andrew J.
    Mak, Raymond H.
    Lanuti, Michael
    Muzikansky, Alona
    Rotow, Julia
    Jaenne, Pasi A.
    Mino-Kenudson, Mari
    Swanson, Scott
    Wright, Cameron D.
    Kozono, David
    Marcoux, Paul
    Piotrowska, Zofia
    Sequist, Lecia, V
    Willers, Henning
    ONCOLOGIST, 2024, 29 (07): : 609 - 618
  • [7] Comment on "Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study"
    Huang, Xiaowei
    Gu, Xian
    Xu, Zhenye
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : e1 - e2
  • [8] To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC
    Bauman, Jessica
    Borghaei, Hossein
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 894 - 896
  • [9] A new standard for EGFR-mutant NSCLC?
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) : 593 - 593
  • [10] A new standard for EGFR-mutant NSCLC?
    David Killock
    Nature Reviews Clinical Oncology, 2019, 16 : 593 - 593
12345